PTPN11 and systemic mastocytosis: Future testing of SHP2 inhibitors, including novel inhibitors with lower IC50 values, will undoubtedly spur further testing of multi-class inhibitors against oncogenic kinases and phosphatases for the treatment of aggressive SM and other cancers.